TPIDB > 臨床試驗主持人
臨床試驗主持人
發表文獻
56筆
11
Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021 Feb;70(2):243-250. doi: 10.1136/gutjnl-2020-322200. Epub 2020 Aug 13. PMID: 32792335; PMCID: PMC7815911.
12
Chiang TH, Chen YN, Chen YR, Tseng YH, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Wu MS, Lin JT, Lee YC. Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study. BMC Gastroenterol. 2022 Feb 18;22(1):69. doi: 10.1186/s12876-022-02155-7. PMID: 35180851; PMCID: PMC8857789.
13
Chiang TH, Chiu SY, Chen SL, Yen AM, Fann JC, Liu CY, Chou CK, Chiu HM, Shun CT, Wu MS, Lin JT, Lee YC, Chen TH, Lin MW. Serum Pepsinogen as a Predictor for Gastric Cancer Death: A 16-Year Community-based Cohort Study. J Clin Gastroenterol. 2019 May/Jun;53(5):e186-e193. doi: 10.1097/MCG.0000000000000992. PMID: 29369241.
14
Chiang TH, Maeda M, Yamada H, Chan CC, Chen SL, Chiu SY, Chen YN, Chou YH, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chen HH, Ushijima T, Graham DY, Lee YC. Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands. J Gastroenterol Hepatol. 2021 Mar;36(3):671-679. doi: 10.1111/jgh.15187. Epub 2020 Jul 24. PMID: 32671873.
15
Chiu HM, Jen GH, Wang YW, Fann JC, Hsu CY, Jeng YC, Yen AM, Chiu SY, Chen SL, Hsu WF, Lee YC, Wu MS, Wu CY, Jou YY, Chen TH. Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers. Gut. 2021 Dec;70(12):2321-2329. doi: 10.1136/gutjnl-2020-322545. Epub 2021 Jan 25. PMID: 33495268; PMCID: PMC8588305.
16
Chiu HM, Su CW, Hsu WF, Jen GH, Hsu CY, Chen SL, Chen HH. Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region. Prev Med. 2021 Oct;151:106622. doi: 10.1016/j.ypmed.2021.106622. Epub 2021 May 25. PMID: 34044024; PMCID: PMC8443175.
17
Chiu HM. Bringing Primary and Secondary Prevention Into Play in Community Prevention of Gastrointestinal Cancers. Gastroenterology. 2021 Dec;161(6):1787-1789. doi: 10.1053/j.gastro.2021.09.006. Epub 2021 Sep 6. PMID: 34499911.
18
Chiu HM. Obesity, metabolic derangement, and the risk of colorectal neoplasm. J Gastroenterol Hepatol. 2021 Jul;36(7):1731-1732. doi: 10.1111/jgh.15584. PMID: 34263484.
19
Chiu PWY, Ng SC, Inoue H, Reddy DN, Ling Hu E, Cho JY, Ho LK, Hewett DG, Chiu HM, Rerknimitr R, Wang HP, Ho SH, Seo DW, Goh KL, Tajiri H, Kitano S, Chan FKL. Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements). Gut. 2020 Jun;69(6):991-996. doi: 10.1136/gutjnl-2020-321185. Epub 2020 Apr 2. PMID: 32241897; PMCID: PMC7211066.
20
Chou CK, Chen CC, Chen CC, Wu JF, Liao WC, Chiu HM, Wang HP, Wu MS, Tseng PH. Positive and negative impact of anti-reflux mucosal intervention on gastroesophageal reflux disease. Surg Endosc. 2022 Sep 15. doi: 10.1007/s00464-022-09605-z. Epub ahead of print. PMID: 36109362.
